Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Journal:

Cancer Research

Published:

2025-09-15

DOI:

10.1158/0008-5472.can-25-1507

Affiliations:

6

Authors:

24

Go to article

Institutions	Authors	Share
Mirati Therapeutics, Inc., United States of America (USA)	9.000000	0.38
UNC Lineberger Comprehensive Cancer Center, United States of America (USA)	6.833333	0.28
The University of North Carolina at Chapel Hill (UNC), United States of America (USA)	4.166667	0.17
George Mason University (GMU), United States of America (USA)	3.000000	0.13
Michigan State University (MSU), United States of America (USA)	1.000000	0.04

Interested in Oncology and Carcinogenesis?